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Abstract: Comparative analyses of the characteristics of persons living with HIV infection (PLWH) in the United States 
(US) captured in surveillance and other observational databases are few. To explore potential joint data use to guide HIV 
treatment and prevention in the US, we examined three CDC-funded data sources in 2012: the HIV Outpatient Study 
(HOPS), a multisite longitudinal cohort; the Medical Monitoring Project (MMP), a probability sample of PLWH receiving 
medical care; and the National HIV Surveillance System (NHSS), a surveillance system of all PLWH. Overall, data from 
1,697 HOPS, 4,901 MMP, and 865,102 NHSS PLWH were analyzed. Compared with the MMP population, HOPS 
participants were more likely to be older, non-Hispanic/Latino white, not using injection drugs, insured, diagnosed with 
HIV before 2009, prescribed antiretroviral therapy, and to have most recent CD4+ T-lymphocyte cell count ≥500 
cells/mm3 and most recent viral load test <200 copies/mL. The MMP population was demographically similar to all 
PLWH in NHSS, except it tended to be slightly older, HIV diagnosed more recently, and to have AIDS. Our comparative 
results provide an essential first step for combined epidemiologic data analyses to inform HIV care and prevention for 
PLWH in the US.  
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INTRODUCTION 
 For the estimated 914,000 persons living with diagnosed 
HIV infection in the United States (US) [1], many of whom 
are engaged in HIV care to various degrees [1-3], describing 
the epidemiology of chronic HIV infection and short- and 
long-term clinical outcomes warrant multifaceted approaches 
and data sources [4]. Owing to the reductions in morbidity 
and mortality following the introduction of antiretroviral 
therapy (ART) [5, 6], HIV infection has become a chronic 
condition, with individuals living longer, healthier lives and 
experiencing non-infectious illnesses traditionally associated 
with aging [7-10]. Innovative uses of cross-sectional and 
longitudinal data to assess patterns in medical care may 
guide further improvements in the clinical management of 
persons living with HIV infection and planning for their care 
and prevention services [8, 11, 12].  
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 To this end, the Centers for Disease Control and 
Prevention (CDC) supports complementary data collection 
activities for persons living with HIV infection in the US, 
both research studies and routine surveillance, each with its 
strengths and limitations. The HIV Outpatient Study (HOPS) 
is a prospective cohort of HIV-infected persons receiving 
care at selected HIV specialty clinics in the US [5, 13]. The 
longitudinal nature of HOPS data enables investigation of 
associations between HIV disease, ART and other 
treatments, and a variety of clinical outcomes [5, 14-17]. 
Since HOPS is a convenience sample of patients at selected 
HIV clinics, it is unclear how the findings from HOPS 
reflect those for all patients in HIV care or all persons with 
diagnosed HIV infection. In contrast, the Medical 
Monitoring Project (MMP) is an ongoing, multisite, 
supplemental surveillance system designed to provide 
nationally representative data about medical care, behaviors, 
and health status of HIV-infected adults in the US through 
annual cross-sectional surveys [18]. Each year medical chart 
abstractions and interviews are collected for a different 
sample of persons, which precludes multi-year observation 
of individual patients. Finally, the National HIV Surveillance 
System (NHSS) collects information on all HIV-diagnosed 
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persons in the US, for whom longitudinal HIV laboratory 
assessments, care patterns, and mortality are tracked [1]. 
However, NHSS has limited clinical information on HIV-
related and unrelated conditions and treatments.  
 The primary objective of this paper was to compare 
demographic characteristics of HIV-infected persons in 
HOPS, MMP, and NHSS and to explore potential joint uses 
of these data to improve treatment and prevention services 
for persons living with HIV infection in the US. We also 
sought to address the following two research questions: (1) 
Do characteristics of a convenience sample of patients 
consenting to participation in a large longitudinal HOPS 
cohort approximate those of persons with HIV infection in 
the population-based MMP and all persons living with 
diagnosed HIV infection in the United States?; and (2) Are 
the population-based estimates derived from MMP likely 
applicable to all patients in HIV care in the United States, 
despite the fact that MMP sampling frame only includes 
patients having at least one clinical visit during January - 
April in the year? 
METHODS 
Data Sources 
HIV Outpatient Study (HOPS) 
 HOPS is an ongoing, prospective, observational cohort 
study of HIV-infected adults (age 18 and older) seen at HIV-
specialty clinics since 1993 [13]. As an open cohort, HOPS 
has continued enrollment of new patients, as some patients 
transfer to care at other locations, are lost to follow-up, or 
die. The nine clinics participating in HOPS in 2012 and 
included in this analyses comprise public, private and 
university-based sites and are located in six US cities: 
Tampa, FL; Washington, DC; Denver, CO (3 sites); 
Chicago, IL (2 sites); Stonybrook, NY; and Philadelphia, 
PA. HOPS clinicians have extensive experience treating 
patients living with HIV. Information is abstracted from 
medical records for each visit, entered electronically by 
trained staff (DISCOVERE®; Cerner Corporation, Kansas 
City, MO), compiled centrally, and reviewed and edited 
before being analyzed. Abstracted information includes 
demographic characteristics, risk factors for HIV infection, 
diagnoses, prescribed medications, laboratory values 
(including CD4+ T-lymphocyte cell (CD4) counts and 
plasma HIV viral loads), mortality, and hospitalization 
records (primarily from discharge summaries). Participants 
sign informed consent, and the HOPS protocol has been 
reviewed and approved annually by the institutional review 
boards of CDC (Atlanta, GA) and each local site. This 
analysis uses HOPS dataset available as of March 31, 2015. 
Medical Monitoring Project (MMP) 
 MMP is an on-going HIV surveillance system designed 
to produce nationally representative estimates of behavioral 
and clinical characteristics of HIV-infected adults receiving 
medical care in the US [18-20]. MMP is a complex-sample, 
cross-sectional survey. For the 2012 data collection cycle, 
states and territories were sampled first, followed by 
facilities providing any outpatient HIV care, and then by 
HIV-infected adults (age 18 years and older) who had at 
least one medical care visit during January-April 2012 at 
participating facilities. Data were collected through face-to-
face interviews and medical record abstractions from June 
2012 through April 2013. Variables from medical records 
and sociodemographic and behavioral information from 
structured interviews were ascertained for the 12 months 
prior to and including the date of a participant’s interview. 
All sampled states and territories participated in MMP: 
California, Delaware, Florida, Georgia, Illinois, Indiana, 
Michigan, Mississippi, New Jersey, New York, North 
Carolina, Oregon, Pennsylvania, Puerto Rico, Texas, 
Virginia, and Washington.  
 Of 548 sampled eligible facilities, 467 participated in 
MMP (facility response rate, 85%). Most of the HIV care 
facilities sampled were private practices (51%), followed by 
hospital-based facilities (29%) and community health centers 
(17%). The remainders were clinical research facilities (8%), 
state or local health department clinics (8%), other 
community-based service organizations (5%), and other type 
of facilities (7%). A facility could belong to multiple 
categories. Of 9,394 sampled persons, 4,901 completed the 
interview and had their medical records abstracted (adjusted 
patient-level response rate, 53%). For nationally represent-
ative estimates, data were weighted to adjust for nonresponse 
by using predictors of response. After weighting the data for 
probability of selection and non-response, the 4,901 MMP 
participants were estimated to represent the population of 
476,366 adults with HIV infection receiving medical care in 
the US [18, 19]. 
National HIV Surveillance System (NHSS) 
 We used data from CDC-supported NHSS to determine 
the prevalence of HIV infection among persons 18 years and 
older in the US in 2012. HIV infection is reportable in all 50 
states and the District of Columbia. Cases meeting pre-
requisite data quality criteria (http://www.cdc.gov/hiv/guide 
lines/reporting.html) are reported by local health juris-
dictions to CDC with demographic information, risk factors, 
and clinical information, including acquired immunode-
ficiency syndrome (AIDS) diagnoses, but without personal 
identifying information. We estimated the number of persons 
diagnosed through 2011 and alive at year-end 2012 overall, 
and by age, sex, race/ethnicity, transmission category, year 
of diagnosis (before 2009, during, or after 2009), and 
whether their infection had ever been classified as stage 3 
(AIDS). Data were reported to CDC through December 2014 
and all analyses were adjusted for reporting delays in 
diagnoses and deaths [1]. 
Analyses 
Primary Analysis: Comparison of HOPS and MMP 
 For the primary analysis, for closest correspondence with 
MMP data, we included HOPS participants who met the 
following inclusion criteria: (A) were actively providing data 
to HOPS as of January 1, 2012; (B) were 18 years or older 
by January 1, 2012; (C) had at least one clinic visit between 
January 1, 2012, and April 30, 2012 (clinic visit defined as 
routine, initial, return to active status, event triggered, or 
post-hospital follow up); and (D) were alive in HOPS as of 
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the weighted mean patient interview date in MMP as 
described below.  
 Although the MMP reference population is HIV-infected 
adults receiving medical care in January-April 2012, MMP 
participants were interviewed from June 2012 through April 
2013. Their sociodemographic, behavioral and clinical 
characteristics were collected (by interview or medical chart 
abstraction) for the 12 months prior to the interview. To 
allow for comparability of MMP and HOPS data, the 
demographic and clinical variables in HOPS were defined as 
of the weighted mean (i.e., average) interview date of the 
MMP participants, which was calculated as November 25, 
2012, and spanned the period of the previous 12 months, 
when appropriate. 
  Sociodemographic variables were age, sex at birth, 
race/ethnicity (including non-Hispanic/Latino black or 
African American [referred to as black], non-
Hispanic/Latino white [referred to as white], Hispanic or 
Latino of any race [referred to as Hispanic], and persons of 
other race/ethnicity), HIV acquisition risk group (including 
gay, bisexual and other men who have sex with men [MSM], 
males and females who inject drugs [IDU], heterosexual 
males and females, and persons in other risk categories 
[including hemophilia, perinatal and occupational 
exposures]) and health insurance coverage. Clinical and 
HIV-related variables included year of HIV diagnosis, 
history of AIDS diagnosis by immunologic or clinical 
criteria, antiretroviral (ARV) exposure status, most recent 
CD4 count in the 12 months preceding the interview date 
(weighted mean interview date for HOPS), most recent viral 
load (defined as most recent HIV viral load undetectable or < 
200 copies/mL in the 12 months preceding the interview 
date, the Department of Health and Human Services (DHHS) 
recommended threshold [21]), durable viral suppression 
(defined to include all viral loads in the previous 12 months 
undetectable or < 200 copies/mL; if no viral loads were 
measured then the patient was not considered durably 
suppressed [22]), number of CD4/viral load measurements in 
the 12 months prior to the interview date, at least one viral 
load in each 6-month period prior to the interview date, at 
least one CD4 count measurement in the 12 months prior to 
the interview date, clinical visit frequency and density, and 
number of clinic visits in the 12 months preceding the 
interview date.  
 Summaries of descriptive data were performed using 
SAS version 9.3 (SAS Institute Inc., Cary, NC). For the 
MMP population, we report unweighted frequencies and 
weighted percentages with 95% confidence intervals (CIs) to 
characterize all self-reported and clinical characteristics; the 
weighted estimates are designed to represent the population 
of adults with HIV infection receiving medical care in the 
US from January-April 2012. For continuous variables, we 
report arithmetic means (and geometric means, where 
indicated) and associated standard errors, and medians and 
interquartile ranges (IQRs), which were weighted for MMP. 
For HOPS participants, we estimated standard errors for 
percentages assuming a binomial distribution and computed 
95% CIs. We evaluated differences between means for 
continuous variables in HOPS versus MMP using a z-
statistic; similarly, for percentages we calculated the 
standard error for the difference in percentages using 
established methods described by Fleiss et al. [23] and 
calculated a standard z-statistic.  
Sub-Analysis A: Comparison of HOPS Participants and 
MMP Population to NHSS 
 NHSS collects data on all HIV-diagnosed persons living 
in the US, including persons who are not receiving medical 
care. We compared percentages among HOPS participants, 
the MMP population, and persons in NHSS. NHSS 
percentages are based on a census of all HIV-diagnosed 
persons (i.e., including those not in care) who have been 
reported to NHSS. Since NHSS percentages are known 
population parameters, HOPS or MMP estimates were 
deemed statistically significantly different from NHSS 
parameters if the corresponding 95% CI for HOPS or MMP 
estimates did not include the NHSS value.  
Sub-Analysis B: Comparison of HOPS Participants with at 
Least One Visit in January-April 2012, at Least One Visit 
in January-December 2012, and Visits Only in May-
December 2012 
 Population-based cross-sectional surveillance systems, 
such as MMP, need to define a reference population, which 
for MMP was all HIV-diagnosed persons aged ≥18 years 
who were receiving medical care between January-April 
2012. The 4-month population definition period was adopted 
for MMP as a compromise based on logistical considerations 
(e.g., difficulty in enumerating the sampling frame, effort to 
locate and recruit sampled persons who might have last 
received care over one year ago, etc.) and population 
representativeness (e.g., prior analyses noted that 88% of all 
persons who had at least one clinical visit in the calendar 
year had at least one visit in the first four months of the year) 
[24]. The rationale for a 4-month population definition 
period was established using one dataset and has not been re-
examined recently.  
 To assess the potential bias introduced by using a 4-
month population definition period in the MMP to 
approximate the characteristics of persons who had at least 
one clinical visit in a calendar year, we compared HOPS 
participants using three different study population 
definitions: A) persons who had at least one visit between 
January-April 2012; B) persons who had at least one visit 
between January-December 2012; and C) persons who had 
visits only between May-December 2012. Note that 
populations A and C are mutually exclusive and together 
sum to population B. The clinic visit types included in this 
sub-analysis were the same as in the primary analysis. 
However, for these analyses, clinical and sociodemographic 
characteristics were assessed for the twelve months of the 
2012 calendar year rather than the twelve months prior to the 
weighted mean interview date (November 25, 2012) 
described above. 
 We assessed the statistical differences between HOPS 
populations A and C using chi-square tests for categorical 
variables, Cochran-Armitage trend tests for ordinal variables, 
Student’s t-test for comparing means, and Wilcoxon rank 
sum test for medians of continuous variables. Statistical 
comparisons with p-values <0.05 were considered 
significant. To validate the MMP sampling strategy to obtain 
estimates relevant for all patients in HIV care, we calculated 
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the differences in percentage estimates from HOPS 
population A versus B.  
RESULTS 
Primary Analysis 
 We included 1,697 HOPS and 4,901 MMP participants in 
the primary analysis. After the MMP data were weighted to 
derive national estimates, compared with the MMP 
population, the HOPS participants were older (mean age: 
50.2 years vs 47.3 years), and a higher percentage were white 
(47.8% vs 35.3%) (Table 1). In both HOPS and MMP, most 
persons were MSM (56.2% vs 59.9%, inclusive of both 
MSM and MSM who used injection drugs), but HOPS had 
fewer participants with IDU as their sole risk factor for HIV 
acquisition (7.1% vs 13.2%). The percentage of non-IDU 
heterosexual females was similar in HOPS and MMP (20.4% 
vs 19.4%). Compared with the MMP population, a smaller 
percentage of HOPS participants were diagnosed with HIV 
Table 1. Characteristics of HIV Outpatient Study (HOPS) participants, Medical Monitoring Project (MMP) population, and 
persons living with diagnosed HIV infection in the National HIV Surveillance System (NHSS), United States, 2012. 
 
Characteristic§ 
HOPS (N=1,697) MMP (N=4,901) HOPS vs MMP NHSS (N=865,102) 
No. % (95% CI) No. %‡ (95% CI) P value○ No. % 
Age category, years  
 18-24  14 0.8 (0.4 - 1.3) 144 3.1 (2.3 - 3.9) <0.001 35,381 4.1 
 25-34 131 7.7 (6.4 - 9.0) 579 12.3 (11.2 - 13.3) <0.001 122,361 14.1 
 35-44 324 19.1 (17.2 - 21.0) 1,015 20.7 (19.3 - 22.1) 0.18 215,173 24.9 
 45-54 696 41.0  (38.7 - 43.4) 1,869 37.4 (35.6 - 39.3) 0.02 309,219 35.7 
 55-64 410 24.2 (22.2 - 26.3) 1,066 21.8 (20.3 - 23.3) 0.06 145,202 16.8 
 ≥65 121 7.1 (5.9 - 8.4) 228 4.7 (3.8 - 5.6) 0.04 37,766 4.4 
Mean age (SE), years 50.2 (0.25) 47.3 (0.20) <0.001 46.1 
Median age [IQR], years 50.3 [44.1, 57.0] 47.9 [39.8, 54.5]  46.8 [38.6, 53.6] 
Sex at birth* 
 Male 1,266 74.6 (72.5 - 76.7) 3,625 74.5 (70.9 - 78.0) 0.96 652,701 75.4 
 Female 431 25.4 (23.3 - 27.5) 1,274 25.5 (21.9 - 29.0) 0.96 212,401 24.6 
Race/Ethnicity 
 White, non-Hispanic 811 47.8 (45.4 - 50.2) 1,560 35.3 (27.4 - 43.2) 0.003 281,397 32.5 
 Black, non-Hispanic 607 35.8 (33.5 - 38.1) 2,072 41.6 (31.9 - 51.3) 0.25 367,503 42.5 
 Hispanic or Latino 226 13.3 (11.7 - 14.9) 1,060 18.7 (12.7 - 24.6) 0.09 173,311 20.0 
 Other† 53 3.1 (2.3 - 4.0) 209 4.5 (3.5 - 5.5) 0.04 42,891 5.0 
HIV acquisition risk group 
MSM 931 54.9 (52.5 - 57.2) 2,516 53.9 (49.1 - 58.7) 0.71 448,696 51.9 
IDU-male 70 4.1 (3.2 - 5.1) 422 7.5 (6.1 - 8.9) <0.001 80,317 9.3 
IDU-female 50 3.0 (2.1 - 3.8) 309 5.7 (4.3 - 7.1) 0.001 51,673 6.0 
MSM-IDU 22 1.3 (0.8 - 1.8) 321 6.0 (5.0 - 7.0) <0.001 49,225 5.7 
Heterosexual-male 171 10.1 (8.6 - 11.5) 339 6.5 (5.3 - 7.7) <0.001 68,590 7.9 
Heterosexual-female 347 20.4 (18.5 - 22.4) 944 19.4 (16.9 - 21.9) 0.54 156,114 18.0 
Other 106 6.2 (5.1 - 7.4) 51 1.0 (0.6 - 1.4) <0.001 10,487 1.2 
Year of HIV diagnosis¥ 
 < 2009 1,574 92.8 (91.5 - 94.0) 4153 83.0 (81.5 - 84.5)  <0.001 737,882 85.3 
 2009 and later 122 7.2 (6.0 - 8.4) 748 17.0 (15.5 - 18.5) <0.001 127,220 14.7 
Ever had AIDS as of end of 2012  
Yes 1,088 64.1 (61.8 - 66.4) 3,380 68.3 (66.1 - 70.5) 0.01 493,497 57.0 
No 609 35.9 (33.6 - 38.2) 1,521 31.7 (29.5 - 33.9) 0.01 371,604 43.0 
Footnotes to Table 1. 
Abbreviations: CI = confidence interval; IDU = male or female injection drug user; IQR = Interquartile range; MSM = men who have sex with men; SE=Standard error. 
○ P-values were obtained from z-statistics. 
§ Characteristics for HOPS patients and MMP patients were established based on data collected in the twelve months prior to the MMP’s weighted interview date which was 
November 25, 2012.; characteristics for NHSS were established based on data in the entire 2012 calendar year. 
* Two people with intersex/ambiguous sex from MMP not shown - these people were included in all the analyses.  
‡ MMP data are nationally representative sampling-probability weighted estimates. 
† Other race groups include those of multiple race groups and other, unknown or missing race groups. 
¥ One person had unknown year of HIV diagnosis from the HOPS. 
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infection in 2009 or later (7.2% vs 17.0%), and a smaller 
percentage had AIDS (64.1% vs 68.3%).  
 A higher percentage of HOPS participants had any 
insurance coverage compared to the MMP population 
(91.8% vs 81.5%) and differences by payer type, including 
utilization of Ryan White HIV/AIDS program, were noted 
(Table 2). Compared with the MMP population, a higher 
percentage of HOPS participants had been prescribed ART 
in the past year (96.5% for HOPS vs 92.7% for MMP, 
respectively), and specifically had been prescribed the newer 
classes of ART such as entry or integrase inhibitors (35.6% 
vs 20.4%), had a most recent CD4 count ≥500 cells/mm3 
(58.2% vs 50.1%), had a most recent viral load test that was 
undetectable or <200 copies/mL (84.7% vs 77.3%), and had 
all viral loads in the past 12 months undetectable or <200 
copies/mL (77.7% vs 66.2%). The mean number of HIV 
laboratory measurements (viral load and CD4 count tests) 
was significantly lower for HOPS participants than the MMP 
population, but HOPS patients were more likely to achieve 
recommended viral load monitoring (at least once in each 6-
month period), and to have at least once CD4 count in the 
year (Table 2). 
Sub-Analysis A: Comparison of HOPS Participants and 
MMP Population to NHSS 
 This analysis included NHSS data on 865,102 persons 
who were diagnosed with HIV infection by the end of 2011 
and were alive at the end of 2012. Compared with HIV-
diagnosed persons in NHSS, a lower percentage of HOPS 
participants were aged 18-24 years (0.8% HOPS vs 4.1% 
NHSS, respectively) and a higher percentage were aged 45-
64 years (65.2% vs 52.5%, Table 1). Moreover, a higher 
percentage of HOPS participants compared with persons in 
NHSS were white (47.8% vs 32.5%) and a lower percentage 
were black (35.8% vs 42.5%) and Hispanic (13.3% vs 
20.0%). A lower percentage of HOPS participants had HIV 
acquisition attributed to IDU (7.1% vs 15.3%) and a higher 
percentage were diagnosed before 2009 (92.8% vs 85.3%) 
and ever had AIDS (64.1% vs 57.0%). Compared with HIV-
diagnosed persons in NHSS, the MMP population had a 
similar distribution by age (MMP patients were modestly 
older, by about one year on average), sex at birth, 
race/ethnicity, HIV acquisition risk group, but it had a 
greater percentage of persons HIV diagnosed in 2009 or later 
(17.0% vs 14.7%) as well as persons diagnosed with AIDS 
(68.3% vs 57.0%). 
Sub-Analysis B: Comparison of HOPS Participants with At 
Least One Visit January-April 2012, At Least One Visit 
January-December 2012, and Visits Only May-December 
2012 
 Among the 2,218 HOPS participants who had at least one 
visit (i.e., were “seen”) January-December 2012, 1,697 
(76.5%) HOPS participants had at least one visit January-
April 2012. As suggested by relatively modest differences in 
percentage estimates for population A vs population C for 
most categorical factors, HOPS participants who were seen 
January-April had similar demographic, behavioral, and 
clinical characteristics to HOPS participants who were seen  
 
January-December, except for the percentage with private 
insurance (49.6% vs 53.0%, Table 3). Of note, both 
populations had the same percentage of ART prescription 
(96.5%) and both had similar percentages with most recent 
viral load undetectable or < 200 copies/mL (84.9% vs 
83.6%), but HOPS participants who were seen January-April 
had more visits and CD4 count and viral load tests, and were 
more likely to have at least one viral load in each 6-month 
period (Table 3).  
 Only 521 (23.5%) of HOPS participants who were seen 
in January-December had their sole visit in May-December. 
Persons who were seen only during May-December, and 
thus may have been somewhat less engaged in care, differed 
significantly from those seen in January-April in the 
following ways: they were slightly younger, more likely to 
be male, white, diagnosed with HIV before 2009, and 
privately insured, but less likely to have ever had AIDS 
(Table 3). Although they had nearly identical level of any 
health insurance coverage (91.9% vs 91.8%), the same 
frequency of ART prescription in the year (96.5%), used 
similar classes of ART regimens, and had comparable mean 
CD4 counts, these patients who were only seen in May-
December also had fewer visits and CD4 count and viral 
load measurements, and fewer had their most recent viral 
load undetectable or < 200 copies/mL (79.5% vs 84.9%) as 
compared with patients with at least one visit in January-
April (Table 3). 
DISCUSSION 
 In-depth comparative analysis of multiple data sources 
describing persons living with diagnosed HIV infection is 
important for evidence-based decision making to guide HIV 
prevention and care research and programs. We found that 
participants in the HOPS differed by some demographic and 
clinical characteristics from the MMP population of persons 
receiving HIV medical care during January-April 2012, and 
likewise differed from all persons living with diagnosed HIV 
infection in NHSS. These findings will inform ongoing 
patient enrollment in HOPS to focus on under-represented 
subgroups, including more recently HIV-diagnosed persons, 
younger individuals, and persons who are black or of 
Hispanic/Latino race/ethnicity. The MMP and NHSS 
populations were demographically similar, except a greater 
percentage of persons in MMP were HIV-diagnosed in 2009 
or later and greater percentage have ever been diagnosed 
with AIDS, suggesting that select findings from MMP may 
broadly apply to all adults living with diagnosed HIV 
infection in the US. Since the MMP and NHSS populations 
were demographically similar also suggests, by extension, 
that HIV-diagnosed persons who were in care (the majority) 
were not substantially different by age, sex and 
race/ethnicity from those HIV-diagnosed but not in care (the 
minority) captured through the NHSS; although certain 
differences could be masked in our comparison given that 
the latter group is smaller than the former [3]. Furthermore, 
analyses from HOPS revealed that persons seen in the first 
four months of the calendar year generally resemble in their 
characteristics persons seen for HIV care throughout the 
year, thus providing support for the present MMP sampling 
methodology.  
 
128    The Open AIDS Journal, 2015, Volume 9 Buchacz et al. 
 
Table 2. HIV care-related characteristics of HIV Outpatient Study (HOPS) participants and Medical Monitoring Project (MMP) 
population, United States, 2012. 
 
 HOPS (N=1,697) MMP (N=4,901) 
P Value○ 
Characteristic§ No. (%) (95% CI) No. (%‡) (95% CI) 
Any health insurance coverage† 1,558 91.8  (90.5 - 93.1) 4,051 81.5 (77.5 - 85.5) <0.001 
Healthcare payer type† 
Any payer or insurance¥ 1,620 95.5 (94.5 - 96.5) 4,787 97.7 (96.9 - 98.4) <0.001 
Any private 833 49.1 (46.7 - 51.5) 1,422 30.5 (25.7 - 35.4) <0.001 
Any Medicaid 518 30.5 (28.3 - 32.7) 1,909 38.7 (34.0 - 43.4) 0.001 
Any Medicare 445 26.2 (24.1 - 28.3) 1,276 26.1 (24.7 - 27.5) 0.94 
Any Ryan White 142 8.4 (7.0 - 9.7) 1,992 41.7 (38.9 - 44.5) <0.001 
Any ART prescription in the year 1,637 96.5 (95.6 - 97.3) 4,563 92.7 (91.8 - 93.6) <0.001 
Any ART prescription in a given class in year 
Any NNRTI 734 43.3 (40.9 - 45.6) 2,092 46.7 (44.9 - 48.5) 0.35 
Any PI 741 43.7 (41.3 - 46.0) 2,441 52.5 (50.6 - 54.4) <0.001 
Any entry or integrase inhibitor 604 35.6 (33.3 - 37.9) 935 20.4 (18.6 - 22.2) <0.001 
Last CD4 count, cells/mm3 
Missing/unknown 52 3.1 (2.2 - 3.9) 257 5.9 (4.7 - 7.1) <0.001 
0-199 123 7.2 (6.0 - 8.5) 477 9.4 (8.1 - 10.7) 0.02 
200-349 214 12.6 (11.0 - 14.2) 694 13.6 (12.0 - 15.1) 0.38 
350-499 321 18.9 (17.1 - 20.8) 1,013 21.0 (19.5 - 22.5) 0.08 
≥ 500 987 58.2 (55.8 - 60.5) 2,460 50.1 (48.0 - 52.2) <0.001 
CD4 count, population geometric mean (SE) 598.4 (7.64) 553.4 (6.79) <0.001 
CD4 count, median [IQR] 564.0 [386.5, 776.7] 520.9 [355.3, 714.7]  
Last VL undetectable or <200 copies/mL 1,438 84.7 (83.0 - 86.5) 3,829 77.3 (75.4 - 79.2) <0.001 
All VLs in the year undetectable or <200 copies/mL 1,318 77.7 (75.7 - 79.7) 3,283 66.2 (64.1 - 68.3) <0.001 
Mean number of CD4/VL tests in the year (SE)  2.5 (0.02) 2.9 (0.05) <0.001 
Median number of CD4/VL in the year [IQR]  2.0 [2.0, 3.0] 2.4 [1.4 -3.3]  
% with number of CD4/VL in the year 
0 or none documented  47 2.8 (2.0 - 3.6) 215 4.9 (3.7 - 6.0) 0.003 
1 214 12.6 (11.0 - 14.2) 519 10.6 (9.4 - 11.9) 0.05 
2 639 37.7 (35.3 - 40.0) 1,131 23.4 (20.9 - 25.8) <0.001 
3 519 30.6 (28.4 - 32.8) 1,471 30.4 (28.5 - 32.2) 0.89 
4+ 278 16.4 (14.6 - 18.1) 1,565 30.7 (27.7 - 33.7) <0.001 
At least one VL in each 6 month period 1,265 74.5 (72.5 - 76.6) 3,489 70.7 (68.4 - 72.9) 0.01 
At least one CD4 in the year 1,645 96.9 (96.1 - 97.8) 4,646 94.1 (92.9 - 95.4) <0.001 
Footnotes to Table 2.  
Abbreviations: ART=Antiretroviral therapy; CD4=CD4+ T-lymphocyte cell; CI = confidence interval; IQR = Interquartile range; MSM = men who have sex with men; NNRTI=non-
nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; SE=Standard error; VL=HIV viral load. 
§ Characteristics for HOPS patients and MMP patients were established based on data collected in the twelve months prior to the MMP’s weighted interview date which was 
November 25, 2012.  
† In MMP, we are relying on self-reported information on any payer(s) that patient may have in the past 12 months. In HOPS, we are relying on chart-abstracted information on any 
primary and secondary (if available) payers documented during HOPS clinic visits in the past 12 months. 
○ P-values were obtained from z-statistics. 
¥ Any Health Insurance Coverage was defined as Private, Other, Medicare, Medicaid, Ryan White and Public Insurance (excluding Self Pay and Clinical Study). Ryan White 
coverage was counted as any payer type but not considered insurance. Please note: Medicaid is a US government insurance program for persons of all ages whose income and 
resources are insufficient to pay for health care. Medicare is a US government insurance program for Americans aged 65 and older who have worked and paid into the system as well 
as for younger people with disabilities, end stage renal disease and amyotrophic lateral sclerosis. The Ryan White HIV/AIDS Program provides HIV-related services in the United 
States for those who do not have sufficient health care coverage or financial resources for coping with HIV disease. The program fills gaps in care not met by other payers. 
‡ MMP data are nationally representative sampling-probability weighted estimates. 
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Table 3. Characteristics of HIV Outpatient Study (HOPS) participants seen in the January-April 2012, compared with those seen 
January-December 2012, and those seen only in May-December 2012. 
 
 
HOPS A (N=1,697) 
One Visit January-
April 
HOPS B (N=2,218) 
One Visit January-
December 
% 
HOPS C (N=521) 
One Visit May-December 
But No Visit January-April 
P Value○ 
Characteristic§ No. % (95% CI) No. % (95% CI) A - B No. % (95% CI) A vs C 
Age category, years 
 18-24 19 1.1 (0.6-1.6) 26 1.2 (0.7-1.6) -0.1 7 1.3 (0.4-2.3) 0.07 
 25-34 142 8.4 (7.0-9.7) 183 8.3 (7.1-9.4) 0.1 41 7.9 (5.5-10.2)  
 35-44 359 21.2 (19.2-23.1) 484 21.8 (20.1 -23.5) -0.6 125 24.0 (20.3-27.7)  
 45-54 681 40.1 (37.8-42.5) 902 40.7 (38.6-42.7) -0.6 221 42.4 (38.2-46.7)  
 55-64 404 23.8 (21.8-25.8) 513 23.1 (21.4-24.9) 0.7 109 20.9 (17.4-24.4)  
 ≥ 65 92 5.4 (4.3-6.5) 110 5.0 (4.1-5.9) 0.4 18 3.5 (1.9-5.0)  
Mean age (SE), years 49.3 (0.25) 49.1 (0.22)  48.4 (0.42) 0.04 
Median age [IQR], years 49.4 [43.2, 56.1] 49.3 [43.0, 55.8]  48.8 [42.8, 54.8] 0.07 
Sex at birth 
Male 1,266 74.6 (72.5-76.7) 1,681 75.8 (74.0-77.6) -1.2 415 79.7 (76.2-83.1) 0.02 
Female 431 25.4 (23.3-27.5) 537 24.2 (22.4-26.0) 1.2 106 20.3 (16.9-23.8)  
Race/ethnicity 
White, non-Hispanic 811 47.8 (45.4-50.2) 1,112 50.1 (48.1-52.2) -2.3 301 57.8 (53.5-62.0) 0.001 
Black, non-Hispanic 607 35.8 (33.5-38.1) 754 34.0 (32.0-36.0) 1.8 147 28.2 (24.3-32.1)  
Hispanic or Latino 226 13.3 (11.7-14.9) 287 12.9 (11.5-14.3) 0.4 61 11.7 (8.9-14.5)  
Other† 53 3.1 (2.3-4.0) 65 2.9 (2.2-3.6) 0.2 12 2.3 (1.0-3.6)  
HIV acquisition risk group 
MSM 931 54.9 (52.5-57.2) 1,254 56.5 (54.5-58.6) -1.6 323 62.0 (57.8-66.2) 0.051 
IDU-male 70 4.1 (3.2-5.1) 92 4.1 (3.3-5.0) 0.0 22 4.2 (2.5-6.0)  
IDU-female 50 2.9 (2.1-3.8) 62 2.8 (2.1-3.5) 0.1 12 2.3 (1.0-3.6)  
MSM-IDU 22 1.3 (0.8-1.8) 23 1.0 (0.6-1.5) 0.3 1 0.2 (0.0-0.6)  
Heterosexual-male 171 10.1 (8.6-11.5) 219 9.9 (8.6-11.1) 0.2 48 9.2 (6.7-11.7)  
Heterosexual-female 347 20.4 (18.5-22.4) 434 19.6 (17.9-21.2) 0.8 87 16.7 (13.5-19.9)  
Other 106 6.2 (5.1-7.4) 134 6.0 (5.0-7.0) 0.2 28 5.4 (3.4-7.3)  
Year of HIV diagnosis¥ 0.04 
< 2009 1,574 92.8 (91.5-94.0) 2071 93.4 (92.3-94.4) -0.6 497 95.4 (93.6-97.2)  
2009 and later 122 7.2 (6.0-8.4) 146 6.6 (5.5-7.6) 0.6 24 4.6 (2.8-6.4)  
Ever had AIDS as of end of 2012 1,088 64.1 (61.8-66.4) 1,397 63.0 (61.0-65.0) 1.1 309 59.3 (55.1-63.5) 0.047 
Any health insurance coverage 1,558 91.8 (90.5-93.1) 2,037 91.8 (90.7-93.0) 0.0 479 91.9 (89.6-94.3) 0.92 
Healthcare payer type† 
Any payer or insurance‡ 1,620 95.5 (94.5-96.5) 2,114 95.3 (94.4-96.2) 0.2 494 94.8 (92.9-96.7) 0.54 
Any private 841 49.6 (47.2-51.9) 1,176 53.0 (50.9-55.1) -3.4 335 64.3 (60.2-68.4) <0.001 
Any Medicaid 504 29.7 (27.5-31.9) 596 26.9 (25.0-28.7) 2.8 92 17.7 (14.4-20.9) <0.001 
Any Medicare 445 26.2 (24.1-28.3) 539 24.3 (22.5-26.1) 1.9 94 18.0 (14.7-21.4) <0.001 
Any Ryan White 143 8.4 (7.1-9.7) 169 7.6 (6.5-8.7) 0.8 26 5.0 (3.1-6.9) 0.01 
Any ART prescription in 2012 1,637 96.5 (95.6-97.3) 2,140 96.5 (95.7-97.3) 0.0 503 96.5 (95.0-98.1) 0.93 
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HOPS A (N=1,697) 
One Visit January-
April 
HOPS B (N=2,218) 
One Visit January-
December 
% 
HOPS C (N=521) 
One Visit May-December 
But No Visit January-April 
P Value○ 
Characteristic§ No. % (95% CI) No. % (95% CI) A - B No. % (95% CI) A vs C 
Any ART prescription in a given class in 2012 
Any NNRTI 738 43.5 (41.1-45.8) 977 44.0 (42.0-46.1) -0.5 239 45.9 (41.6-50.2) 0.34 
Any PI 735 43.3 (41.0-45.7) 936 42.2 (40.1-44.3) 1.1 201 38.6 (34.4-42.8) 0.06 
Any entry or integrase inhibitor 606 35.7 (33.4-38.0) 783 35.3 (33.3-37.3) 0.4 177 34.0 (29.9-38.1) 0.47 
Last CD4 count, cells/mm3 
Missing/unknown 46 2.7 (1.9-3.5) 72 3.2 (2.5-4.0) -0.5 26 5.0 (3.1-6.9) 0.69 
0-199 123 7.2 (6.0-8.5) 178 8.0 (6.9-9.2) -0.8 55 10.6 (7.9-13.2)  
200-349 221 13.0 (11.4-14.6) 271 12.2 (10.9-13.6) 0.8 50 9.6 (7.1-12.1)  
350-499 313 18.4 (16.6-20.3) 395 17.8 (16.2-19.4) 0.6 82 15.7 (12.6-18.9)  
≥ 500 994 58.6 (56.2-60.9) 1,302 58.7 (56.7-60.8) -0.1 308 59.1 (54.9-63.4)  
CD4 count, population geometric mean (SE) 599.5 (7.60) 600.0 (6.73)  601.8 (14.4) 0.89 
CD4 count, median [IQR] 567.6 [386.0, 781.5] 568.6 [386.0, 783.0]  570.0 [386.0, 788.0] 0.68 
Last VL undetectable or <200 copies/ml 1,440 84.9 (83.1-86.6) 1,854 83.6 (82.0-85.1) 1.3 414 79.5 (76.0-82.9) 0.004 
All VLs in the year undetectable or <200 copies/ml 1,330 78.4 (76.4-80.3) 1,713 77.2 (75.5-79.0) 1.2 383 73.5 (69.7-77.3) 0.02 
Mean number of CD4/VL tests in the year (SE)  2.6 (0.03) 3.2 (0.04)  1.7 (0.04) <0.001 
Median number of CD4/VL in the year [IQR]  2 [2, 3] 2 [2, 3]  2 [1, 2] <0.001 
Number of CD4/VL in the year 
0 or none documented 40 2.4 (1.6-3.1) 62 2.8 (2.1-3.5) -0.4 22 4.2 (2.5-6.0) <0.001 
1 207 12.2 (10.6-13.8) 430 19.4 (17.7-21.0) -7.2 223 42.8 (38.5-47.1)  
2 618 36.4 (34.1-38.7) 815 36.7 (34.7-38.8) -0.3 197 37.8 (33.6-42.0)  
3 571 33.6 (31.4-35.9) 627 28.3 (26.4-30.1) 5.3 56 10.7 (8.1-13.4)  
4+ 261 15.4 (13.7-17.1) 284 12.8 (11.4-14.2) 2.6 23 4.4 (2.6-6.2)  
At least one VL in each 6 month period (%) 1,298 76.5 (74.5-78.5) 1,502 67.7 (65.8-69.7) 8.8 204 39.2 (35.0-43.4) <0.001 
At least one CD4 test in the year (%) 1,651 97.3 (96.5-98.1) 2,146 96.8 (96.0-97.5) 0.5 495 95.0 (93.1-96.9) 0.01 
Clinical visitⱡ frequency and density 
Mean (SE) 3.6 (0.05) 3.2 (0.04)  1.9 (0.05) <0.001 
Median [IQR] 3 [2, 4] 3 [2, 4]  2 [1, 2] <0.001 
Min-Max 1-16 1-16  1-8  
Number of clinical visitsⱡ in the year  
1 119 7.0 (5.8-8.2) 348 15.7 (14.2-17.2) -8.7 229 44.0 (39.7-48.2) <0.001 
2 407 24.0 (22.0-26.0) 598 27.0 (25.1-28.8) -3.0 191 36.7 (32.5-40.8)  
3 466 27.5 (25.3-29.6) 534 24.1 (22.3-25.9) 3.4 68 13.1 (10.1-16.0)  
4+ 705 41.5 (39.2-43.9) 738 33.3 (31.3-35.2) 8.2 33 6.3 (4.2-8.4)  
Footnotes to Table 3. 
Abbreviations: ART= Antiretroviral therapy; CD4=CD4+ T-lymphocyte cell; CI = confidence interval; IDU = male or female injection drug user; IQR = Interquartile range; MSM = 
men who have sex with men; NNRTI=non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; SE=Standard error; VL=HIV viral load. 
HOPS A refers to all participant who had at least one outpatient visit during January-April, 2012 (MMP’s current population definition period). 
HOPS B refers to all participant who had at least one outpatient visit during January-December, 2012  
HOPS C refers to all participants who had at least one outpatient visit during May-December, 2012, but had no visit during January-April 2012 (excludes MMP’s current population 
definition period). 
§ Characteristics for HOPS patients were established based on data collected in the 2012 calendar year. Note that this time frame differs from that used in the primary analysis. 
○ P-values for ordinal variables were calculated using Cochran-Armitage trend tests; p-values for categorical variables were calculated using chi-square tests; p-values for 
distributions were obtained from Wilcoxon rank sum tests; and p-values for means were obtained from Student’s t-tests. 
† Other race groups include those of multiple race groups and other, unknown or missing race groups. 
¥ One participant had unknown year of HIV diagnosis. 
† We are relying on chart-abstracted information on any primary and secondary (if available) payers documented during HOPS clinic visits in the past 12 months. 
‡ Any Health Insurance Coverage was defined as Private, Other, Medicare, Medicaid, Ryan White and Public Insurance (excluding Self Pay and Clinical Study). Ryan White 
coverage was counted as any payer type but not considered insurance. Please note: Medicaid is a US government insurance program for persons of all ages whose income and 
resources are insufficient to pay for health care. Medicare is a US government insurance program for Americans aged 65 and older who have worked and paid into the system as well 
as for younger people with disabilities, end stage renal disease and amyotrophic lateral sclerosis. The Ryan White HIV/AIDS Program provides HIV-related services in the United 
States for those who do not have sufficient health care coverage or financial resources for coping with HIV disease. The program fills gaps in care not met by other payers. 
ⱡ Eligible types of clinical visits were defined as: routine, initial, return to active status, event triggered, or post-hospital follow up. 
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 The HOPS 2012 data are based on a convenience sample 
of persons with HIV infection attending nine HOPS-
participating clinics in six US cities, while MMP is a 
probability sample of persons with HIV infection receiving 
medical care in the US; in 2012 MMP data were collected 
from 467 facilities in 16 states and Puerto Rico. Although 
MMP is based on a large, diverse, geographically distributed 
probability sample of facilities, the data collected reflect 
only one year of follow-up time. Thus MMP is designed to 
make accurate estimates of the prevalence of behavioral and 
clinical characteristics among persons with HIV infection 
receiving medical care, but is ill-equipped for longitudinal 
analyses (e.g., estimating incidence rates of conditions and 
studying risk factors for their onset). The average accrued 
follow-up time per HOPS participant in 2012 was eight 
years, making HOPS well poised to assess disease incidence 
as well as risk factors for disease development. However, as 
our analyses revealed, HOPS participants enrolled at selected 
HIV clinics differ in some respects from the overall 
population of persons with HIV infection receiving medical 
care in the US. The HOPS cohort is growing in size with an 
increasing representation of older patients with long-standing 
HIV infection who are surviving longer due to ART. 
Because of resource constraints, not all newly HIV-
diagnosed persons seen at participating clinics can be 
enrolled into observational cohorts [8] like the HOPS, posing 
a challenge with respect to such cohort recruitment strategies 
to continue to reflect characteristics of all contemporary 
persons in HIV care in the US.  
 Moving forward, a data synthesis approach that builds on 
the relative strengths of MMP (ability to estimate 
prevalence) and HOPS (ability to estimate incidence) could 
be developed to improve national epidemiologic data and 
projections needed for HIV prevention and treatment. HOPS 
and MMP data can be used jointly to derive population 
attributable fractions and other estimates for the US 
population. Specifically, HOPS rates can be standardized to 
MMP population prevalence to provide estimates that may 
approximate national rates. For example, HOPS was used to 
estimate the rates of incident cardiovascular disease (CVD) 
events according to patients’ baseline CD4 count and history 
of tobacco use [15]. Applying these HOPS rates to the 
distribution of CD4 count strata and tobacco use history 
from MMP [18] could be used to project the number of 
incident CVD events among these subgroups of patients 
nationally, and inform modeling projections of how many 
CVD events could be averted by earlier ART initiation to 
avoid low CD4 counts and by tobacco cessation 
interventions. 
 Another key consideration in interpreting data from 
HOPS and MMP is that both databases only include persons 
who are receiving medical care. A substantial proportion of 
HIV-infected persons in the US are not consistently engaged 
in HIV care [3, 12]. Some of the noted differences between 
HOPS and NHSS might be due to the nature of the HOPS 
convenience sample (e.g., types of persons who attended the 
nine HOPS-participating clinics in 2012, were systematically 
approached for study participation, and agreed to 
participate). In addition, differences between MMP and 
NHSS populations might reflect differences in care seeking; 
for example persons who have been diagnosed with AIDS 
are more likely to become enrolled in care than persons 
without AIDS. To better understand the needs of HIV-
diagnosed persons not receiving medical care and thereby 
better guide HIV prevention and treatment in the US, in 
2013, CDC re-designed MMP to directly sample from 
NHSS; thus, starting with the 2015 data collection cycle, the 
new MMP reference population will include all HIV-
diagnosed persons in the participating jurisdictions 
regardless of whether they are receiving medical care (see 
http://www.grants.gov/web/grants/search-grants.html, CDC-
RFA-PS15-1503). 
 Although, MMP uses a probability sample, a 
methodology to reduce overall bias [25], the 4-month 
population definition period (i.e., January-April) might skew 
the overall estimates obtained from MMP. In another multi-
site analysis of 12,135 patients in care in 2003, 88% of 
patients had at least one visit in the first four months of the 
year [24]. In our analysis using data from 2012, we found 
that somewhat lower percentage, or 76.5% of HOPS 
participants who had at least one visit January-December 
also had at least one visit in January-April. However, 
persons who had at least one visit January-April and persons 
who had visits only May-December were equally likely to be 
prescribed ART in the year with the only notable differences 
being the percentage with private insurance, the frequency of 
CD4 count and viral load testing, and the percentage 
achieving viral suppression. Our results suggest that persons 
seen in the first four months of the calendar year are a 
reasonable approximation of all persons engaged in care (i.e., 
who have at least one visit in the calendar year). However, 
additional validation studies using other data sources would 
be beneficial to further explore this issue. The estimates from 
the HOPS and MMP are in-line with earlier results from the 
North American AIDS Cohort Collaboration on Research 
and Design, which found that among 35,324 participants 
who had ≥1 HIV care visit from January-June 2008, 82% 
were prescribed ART, and 78% had a suppressed HIV viral 
load [26]. 
 This analysis has certain limitations. Firstly, although we 
attempted to define variables similarly across different data 
sources, estimates may differ to an unknown degree due to 
different data collection methods for some variables (e.g., 
documentation of insurance type per structured interview in 
MMP versus medical record abstraction in the HOPS). 
Secondly, there is no one single gold standard data collection 
system for care indicators for persons living with HIV 
infection, and so all comparisons made in this manuscript 
describe relative differences between data systems, each with 
its own unique strengths and limitations. Thirdly, due to a 
higher average number of viral load measurements in the 
year in the MMP vs the HOPS, the difference in the 
percentage of patients with durable viral suppression across 
these two populations may have been overestimated.  
 In conclusion, CDC currently supports complementary 
data collection systems to describe persons living with 
diagnosed HIV infection to better inform HIV prevention 
and treatment efforts. Understanding the comparative 
strengths and limitations of the individual databases, and 
contrasting database findings, is key to enhancing data 
interpretation and utility. The formal comparison presented 
here is an essential first step to integrating estimates 
produced via the different data systems needed to provide an 
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overall better understanding of HIV epidemiology in the US. 
Our findings also provide a reference point for design and 
interpretation of data from other US-based data collection 
systems, including other large HIV clinical cohorts in North 
America [8], and HIV-infected patients receiving care for 
HIV infection and captured in a variety of health services 
databases.  
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